...
首页> 外文期刊>Regulatory peptides. >Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
【24h】

Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.

机译:利拉鲁肽(而非维格列汀)可恢复2型糖尿病动物模型,即Psammomys obesus的正常血糖和胰岛素含量。

获取原文
获取原文并翻译 | 示例

摘要

In order to investigate the effect and mechanism of liraglutide and vildagliptin in diabetic Psammomys obesus, we examined proliferation and apoptosis of beta-cells, beta-cell mass (BCM), and pancreatic insulin content after zero, six and fourteen days of treatment compared to control groups. One group of animals was kept on low-energy diet and seven groups were given high-energy diet (HED) that induced diabetes over a four week period. Non-fasting morning blood glucose, body weight, HbA(1C) and pancreatic insulin content were measured and beta cell mass (BCM), proliferation and apoptosis frequencies were determined using stereological point counting. Liraglutide significantly reduced blood glucose and even normalized it in all animals treated for six days and in 11 out of 17 animals treated for fourteen days. HED increased BCM and treatment with liraglutide did not change this. However, compared to the vehicle-treated animals pancreatic insulin content was normalized in animals treated for six and fourteen days with liraglutide. In contrast, vildagliptin, in doses causing full inhibition of plasma DPP-IV activity, neither reduced blood glucose nor altered HED-induced increases in BCM or pancreatic insulin content. These results suggest that liraglutide restores normoglycaemia and improves glycaemic control in P. obesus by increasing their insulin content and improving the function of the beta-cells. In contrast, vildagliptin does not improve glycaemic control in P. obesus nor affect beta-cell insulin content.
机译:为了研究利拉鲁肽和维格列汀在糖尿病性沙门氏菌中的作用和机制,我们比较了零,六和十四天治疗后β细胞,β细胞质量(BCM)和胰腺胰岛素含量的增值和凋亡情况。对照组。一组动物保持低能量饮食,七组动物接受高能量饮食(HED),在四个星期内诱发糖尿病。测量非空腹早晨血糖,体重,HbA(1C)和胰腺胰岛素含量,并使用体视学点计数法测定β细胞质量(BCM),增殖和凋亡频率。利拉鲁肽可显着降低血糖,甚至在治疗6天的所有动物中以及在治疗14天的17只动物中的11只中均将其恢复正常。 HED增加了BCM,利拉鲁肽治疗并没有改变这一情况。但是,与用赋形剂处理的动物相比,用利拉鲁肽治疗六和十四天的动物的胰脏胰岛素含量正常化。相反,维达列汀在引起血浆DPP-IV活性完全抑制的剂量下,血糖既未降低,也未改变HED引起的BCM或胰腺胰岛素含量的增加。这些结果表明,利拉鲁肽可通过增加它们的胰岛素含量和改善β细胞的功能来恢复正常血糖,并改善他们的血糖控制。相比之下,维格列汀既不能改善肥胖假单胞菌的血糖控制,也不会影响β细胞胰岛素的含量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号